|
||
| |||||||
|
Peakdale Molecular appoints Glenn Killingworth to strengthen US Sales
Chapel-en-le-Frith, UK, December 20,
2004 – Peakdale Molecular Ltd announces the appointment of Glenn
Killingworth as Business Development Manager as part of the Company’s strategy
to expand its US market share. Glenn combines a wealth of experience of
sales, marketing and business development in the US and Europe with a strong
scientific background.
He joins Peakdale from his most recent position as
Business Development Manager at Chemical Synthesis Services (CSS), Northern
Ireland, where he worked with both European and US-based companies and built a
proven track record of commercial success. Previous to CSS, he was Business
Development Manager at Fisher Scientific UK, where he achieved the successful
introduction of Fisher Scientifics’ custom synthesis business in the US.
His sales and marketing experience is supported by
his strong technical and scientific background gained as Project Chemist at
Synprotec and as an Analytical Chemist for Hillsdown Food Product Ltd. Glenn
also holds a Bachelor of Science with Honours from the Manchester Metropolitan
University, UK.
Kimberley Morrison, CEO of Peakdale Molecular,
commented, “Glenn’s appointment reflects the importance of the US market for
Peakdale and will strengthen our positioning. We are delighted that an
individual of his calibre has joined the Company. I anticipate that he will
make a valuable contribution in our drive to expand our US market share.
Importantly, our customers in the US will benefit from his experience in
chemistry services and custom synthesis.”
“I am pleased to join Peakdale as part of the
sales team at an exciting time in the Company’s expansion”, added Glenn. “I
particularly admire Peakdale’s innovative approaches in custom synthesis and
the development of the GPCR-targeted screening libraries and look forward to
working with new customers and providing the Company’s unique chemistry
know-how.”
About Peakdale Molecular Ltd:
Peakdale Molecular was founded in 1992. Today, the Company’s customers include global pharmaceutical majors and an increasing number of biotechnology companies. Its team of chemists combines experience in pharmaceutical R&D and process development, fine chemicals, parallel synthesis and medicinal chemistry to deliver unique chemistry solutions to a range of drug discovery challenges. Peakdale operates in several distinct markets providing novel screening compounds, GPCR-targeted libraries, catalogue intermediates, custom synthesis and contract research chemistry. Further information about the Company can be obtained at www.peakdale.co.uk.
|
|
| ||||||||